These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

530 related items for PubMed ID: 11799629

  • 1. [Gram-positive bacterial infections resistant to antibiotic treatment].
    Utili R.
    Ann Ital Med Int; 2001; 16(4):205-19. PubMed ID: 11799629
    [Abstract] [Full Text] [Related]

  • 2. Gram-positive bacterial resistance. A challenge for the next millennium.
    Bassetti M, Melica G, Cenderello G, Rosso R, Di Biagio A, Bassetti D.
    Panminerva Med; 2002 Sep; 44(3):179-84. PubMed ID: 12094131
    [Abstract] [Full Text] [Related]

  • 3. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria.
    Rybak MJ.
    Clin Microbiol Infect; 2006 Mar; 12 Suppl 1():24-32. PubMed ID: 16445721
    [Abstract] [Full Text] [Related]

  • 4. Antimicrobial resistance in gram-positive bacteria.
    Rice LB.
    Am J Infect Control; 2006 Jun; 34(5 Suppl 1):S11-9; discussion S64-73. PubMed ID: 16813977
    [Abstract] [Full Text] [Related]

  • 5. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).
    Sader HS, Watters AA, Fritsche TR, Jones RN.
    BMC Infect Dis; 2007 Apr 18; 7():29. PubMed ID: 17442104
    [Abstract] [Full Text] [Related]

  • 6. Current challenges in antibiotic resistance.
    Hand WL.
    Adolesc Med; 2000 Jun 18; 11(2):427-38. PubMed ID: 10916132
    [Abstract] [Full Text] [Related]

  • 7. Aminoglycoside resistant enterococcal endocarditis.
    Eliopoulos GM.
    Infect Dis Clin North Am; 1993 Mar 18; 7(1):117-33. PubMed ID: 8463648
    [Abstract] [Full Text] [Related]

  • 8. Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria.
    Appelbaum PC, Jacobs MR.
    Curr Opin Microbiol; 2005 Oct 18; 8(5):510-7. PubMed ID: 16098786
    [Abstract] [Full Text] [Related]

  • 9. Antimicrobial resistance in gram-positive bacteria.
    Rice LB.
    Am J Med; 2006 Jun 18; 119(6 Suppl 1):S11-9; discussion S62-70. PubMed ID: 16735146
    [Abstract] [Full Text] [Related]

  • 10. Newer developments in the treatment of Gram-positive infections.
    Koomanachai P, Crandon JL, Nicolau DP.
    Expert Opin Pharmacother; 2009 Dec 18; 10(17):2829-43. PubMed ID: 19929705
    [Abstract] [Full Text] [Related]

  • 11. [An alarming problem in the therapy of infective endocarditis: the development of antibiotic-resistant strains].
    Enia F, Bella R, Mineo R, Mizio G, Reina G.
    Ital Heart J Suppl; 2005 Mar 18; 6(3):121-7. PubMed ID: 15875497
    [Abstract] [Full Text] [Related]

  • 12. Vancomycin-resistant Enterococcus faecium infections in the ICU and quinupristin/dalfopristin.
    Zervos M.
    New Horiz; 1996 Aug 18; 4(3):385-92. PubMed ID: 8856757
    [Abstract] [Full Text] [Related]

  • 13. Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwide.
    Sader HS, Streit JM, Fritsche TR, Jones RN.
    Diagn Microbiol Infect Dis; 2004 Nov 18; 50(3):201-4. PubMed ID: 15541606
    [Abstract] [Full Text] [Related]

  • 14. Optimizing therapy for vancomycin-resistant enterococci (VRE).
    Linden PK.
    Semin Respir Crit Care Med; 2007 Dec 18; 28(6):632-45. PubMed ID: 18095227
    [Abstract] [Full Text] [Related]

  • 15. Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential.
    Rubinstein E, Bompart F.
    J Antimicrob Chemother; 1997 May 18; 39 Suppl A():139-43. PubMed ID: 9511078
    [Abstract] [Full Text] [Related]

  • 16. Patterns of isolation of common gram positive bacterial pathogens and their susceptibilities to antimicrobial agents in Jimma Hospital.
    Gebreselassie S.
    Ethiop Med J; 2002 Apr 18; 40(2):115-27. PubMed ID: 12240573
    [Abstract] [Full Text] [Related]

  • 17. [Linezolid in the treatment of antibiotic-resistant gram-positive infections of the musculoskeletal system].
    Jahoda D, Nyc O, Pokorný D, Landor I, Sosna A.
    Acta Chir Orthop Traumatol Cech; 2006 Oct 18; 73(5):329-33. PubMed ID: 17140514
    [Abstract] [Full Text] [Related]

  • 18. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.
    Cafini F, Aguilar L, González N, Giménez MJ, Torrico M, Alou L, Sevillano D, Vallejo P, Prieto J.
    J Antimicrob Chemother; 2007 Jun 18; 59(6):1185-9. PubMed ID: 17412725
    [Abstract] [Full Text] [Related]

  • 19. Current and emerging serious Gram-positive infections.
    Menichetti F.
    Clin Microbiol Infect; 2005 May 18; 11 Suppl 3():22-8. PubMed ID: 15811021
    [Abstract] [Full Text] [Related]

  • 20. Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid.
    Johnson AP, Mushtaq S, Warner M, Livermore DM.
    Int J Antimicrob Agents; 2004 Oct 18; 24(4):315-9. PubMed ID: 15380254
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.